Degarelix
Also referenced as: Firmagon
A GnRH antagonist used for androgen suppression in advanced prostate cancer.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Firmagon is FDA-approved for advanced prostate cancer.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GnRH antagonist used for androgen suppression in advanced prostate cancer.
Firmagon is FDA-approved for advanced prostate cancer.
This medicine lowers testosterone; it is not a testosterone-enhancement or libido therapy.
Why It's Being Studied
- Advanced prostate cancer
- Androgen deprivation
Mechanism of Action
GnRH-receptor blockade suppresses testosterone without the initial stimulation typical of an agonist.
GnRH-receptor blockade suppresses testosterone without the initial stimulation typical of an agonist. This medicine lowers testosterone; it is not a testosterone-enhancement or libido therapy.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Advanced prostate cancer
- Androgen deprivation
- Subcutaneous approved medicine
Evidence Summary
Clinical research supports disease-specific androgen suppression.
Higher tiers carry more weight. Filled tiers have evidence for Degarelix; tap to read it.
- Clinical research supports disease-specific androgen suppression.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Clinical research supports disease-specific androgen suppression.
Reported Adverse Events in Research
- Injection reactions, hot flushes, QT prolongation and consequences of androgen deprivation require attention.
Limitations of Current Evidence
- This medicine lowers testosterone; it is not a testosterone-enhancement or libido therapy.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Degarelix | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Degarelix — prescribing label